Adults with obesity receiving tirzepatide 10 mg or 15 mg may be able to maintain most of their weight loss after switching to ...

People who stop using GLP-1s tend to regain much of the lost weight. Two new studies identify strategies that can help stave this off. Two new clinical trials suggest options for maintaining weight ...

Two phase 3b trials evaluated the efficacy and safety of tirzepatide or orforglipron for weight maintenance after injectable incretin treatment.

Eli Lilly and Novo Nordisk are building cases for their incretin drugs both new and old as attractive weight loss maintenance ...

New research presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May) and published in Nature ...

New research presented at the European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12–15 May) and published in The Lancet shows that people who have lost weight using the maximum tolerated ...

Novo Nordisk has identified a group of early responders to its high-dose Wegovy formulation that shed almost 28% of their ...

India has become one of the first countries to introduce cheaper, generic brands of weight loss drugs like Ozempic and Wegovy ...

These drugs fall into a class known as GLP-1s, mimicking a natural hormone that helps regulate blood sugar, slows how quickly ...

Ozempic (semaglutide) and Mounjaro (tirzepatide) are injectable type 2 diabetes medications prescribed to lower blood sugar, but they have different mechanisms of action. These medications have also ...

Researchers conducted a systematic review and meta-analysis to compare glycemia and weight loss outcomes between tirzepatide and semaglutide doses. High-dose tirzepatide (15 mg) was more effective for ...

Research shows that individuals using GLP-1 medications for weight loss, such as Ozempic, regain nearly 22 pounds within 18 months of stopping.  | Health ...